Overview
Researchers are trying to determine if subjects with diabetic gastroparesis and symptoms of bloating will have a greater improvement in bloating symptoms when treated with rifaximin.
Eligibility
Inclusion Criteria
- Men and women adult patients, aged 18-75, with diabetic gastroparesis
- Diagnosis of diabetic gastroparesis will have been made previously using a combination of symptoms (e.g., nausea, vomiting, bloating, early satiety, abdominal pain), the absence of mechanical obstruction, and delayed gastric emptying using a 4-hour, solid phase scintigraphic study (GES; > 20% remaining at 4 hours)
Exclusion Criteria
- Prior surgery to the stomach or esophagus
- Known mechanical obstruction of the GI tract
- Current or recent (< 4 weeks) use of opioids
- Current/active use of cannabis
- Current or recent (< 4 weeks) use of antibiotics
- Current or recent use of antifungal agents (< 4 weeks)
- Prior treatment with rifaximin (< 1 year)
- Uncontrolled diabetes with a HgbA1c > 12
- Severe uncontrolled or untreated anxiety or depression.